Through this screen, we found that neurotrophin tyrosine kinase receptor 3 (NTRK3) acts as either a tumor-suppressor gene or an oncogene in the development of various cancers and that its mutation status (mutant-type NTRK3, NTRK3-MT) can predict the prognosis of patients with LUAD treated with ICIs. This evidence concerns the gene NTRK3 and neoplasm.